Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)

Status: Recruiting
Location: See all (11) locations...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called overdiagnosis). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of overdiagnosis. This study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 30
Maximum Age: 74
Healthy Volunteers: t
View:

• Female\*

• Age 30 years to 74 years old

• Reside in California, North Dakota, South Dakota, Iowa, Minnesota, Alabama, Louisiana, Illinois OR have coverage from a participating health plan\*\*.

⁃ NOTE\*: As of 2019, we are now enrolling all persons who identify as female, and will capture both their sex at birth and gender identity in the baseline survey.

⁃ NOTE\*\*: Depending on funding for study services, recruitment will expand nationwide, therefore criteria (c) will not apply if funding allows. As of 2019, recruitment is available nationwide.

Locations
United States
Alabama
University of Alabama at Birmingham
RECRUITING
Birmingham
California
University of California Irvine
RECRUITING
Irvine
University of California Los Angeles
RECRUITING
Los Angeles
University of California Davis
RECRUITING
Sacramento
University of California San Diego
RECRUITING
San Diego
University of California San Francisco
RECRUITING
San Francisco
Florida
TopLine MD Alliance
RECRUITING
Miami
Illinois
University of Chicago
RECRUITING
Chicago
Louisiana
Louisiana State University
ACTIVE_NOT_RECRUITING
New Orleans
New York
Weill Cornell Medicine
RECRUITING
New York
South Dakota
Edith Sanford Breast Center
ACTIVE_NOT_RECRUITING
Sioux Falls
Contact Information
Primary
Allison Fiscalini, MPH
allison.stoverfiscalini@ucsf.edu
(415) 476-0267
Backup
Jennifer Atamer
Jennifer.atamer@ucsf.edu
Time Frame
Start Date: 2016-08-31
Estimated Completion Date: 2026-09-01
Participants
Target number of participants: 100000
Treatments
Active_comparator: Annual Arm
Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
Experimental: Risk-Based Arm
Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
Authors
Related Therapeutic Areas
Sponsors
Collaborators: Breast Cancer Research Foundation, United States Department of Defense, Safeway Foundation, Robert Wood Johnson Foundation, National Cancer Institute (NCI), Color Genomics, Inc., Patient-Centered Outcomes Research Institute, Salesforce
Leads: University of California, San Francisco

This content was sourced from clinicaltrials.gov